CA-AGENDIA-INC
11.12.2020 15:47:12 CET | Business Wire | Press release
Agendia, Inc. , a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van ’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint® , Agendia’s 70-gene breast cancer recurrence assay, to further stratify patients with clinically low risk breast cancer which could impact physician-patient discussions and treatment planning.
MINDACT (Microarray In Node-Negative and 1-3 node-positive Disease may Avoid ChemoTherapy), the Phase 3, prospective, randomized clinical trial supported by the European Organization for Research and Treatment of Cancer (EORTC), was designed to determine whether MammaPrint could be used to safely de-escalate patients with early stage breast cancer from chemotherapy without compromising their outcomes. Updated outcome and treatment data from the trial shared at SABCS 2020 build upon nearly 9-year follow-up results debuted at ASCO 2020 and confirm MINDACT as a positive de-escalation study.
Dr. van ’t Veer’s presentation showed that the combination of clinical low risk and MammaPrint Low Risk results indicate excellent 8-year prognosis – these patients showed a distant metastasis-free survival rate of 94.7% with no chemotherapy. Of note, amongst the clinically low risk study population, distant metastasis free survival at 8 years was 3.6% better in MammaPrint Low Risk patients as compared to those with a High Risk result.
“Collectively, these data produce a significant library of evidence that will allow for the precise treatment of breast cancer, including insights into a patient population considered low risk,” said Dr. van ’t Veer. “Within this population, further stratification by genomic signature into MammaPrint Low or High Risk should be weighed for further treatment planning.”
These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint® , the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint® , the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Brings Interactive iOS Notifications to Select Smartwatches in Europe25.6.2026 16:50:00 CEST | Press release
New Beta feature allows eligible iPhone users to reply, take action and view supported notification images directly from their wrist Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced its support of iOS Notification Forwarding, a new Beta feature that provides eligible iPhone users in the European Union with a more complete notification experience on select Amazfit smartwatches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625552705/en/ Amazfit brings interactive iOS notifications to select smartwatches in Europe, allowing users to interact with supported notifications directly from their watch. The feature goes beyond basic notification alerts, allowing users to interact with supported notifications directly from their watch. Depending on the notification type, users may be able to reply to messages, complete quick actions such as Mark as Read or Call Back, and view supported images fr
Quorum Software Acquires Streamba to Extend Leadership as the AI Platform for the Energy Value Chain25.6.2026 16:35:00 CEST | Press release
Acquisition brings Streamba's AI-native logistics platform and VOR intelligence layer into Quorum’s unified energy data – closing the loop between planning, field execution and supply chain in real time Quorum Software, a global leader in energy software, today announced the acquisition of Streamba, an AI-native supply chain platform purpose-built for energy. This acquisition advances Quorum's position as the AI platform for the energy industry — embedding intelligent, real-time orchestration across upstream, midstream, measurement, SCADA and supply chain. For the first time, energy operators can connect planning, execution and back office in a single, AI-powered system. Quorum has built a comprehensive energy software platform through sustained innovation and strategic acquisitions, spanning planning, production operations, measurement, accounting, hydrocarbon management and logistics. Streamba’s Visibility, Orchestration and Response (VOR) platform adds a centralized operational inte
Clearwater Analytics Completes $8.4 Billion Take-Private Acquisition by Permira and Warburg Pincus25.6.2026 16:07:00 CEST | Press release
Acquisition supported by Francisco Partners, with participation from TemasekStockholders receive $24.55 per share Clearwater Analytics (“CWAN”, “Clearwater” or the “Company”), today announced the completion of its previously announced acquisition, a transaction valued at approximately $8.4 billion, by a Permira and Warburg Pincus-led Investor Group (the “Investor Group”). The transaction was supported by Francisco Partners, with participation from Temasek. With the completion of the acquisition, Clearwater’s Class A common stock no longer trades on the New York Stock Exchange. Under the terms of the agreement, Clearwater stockholders received $24.55 per share in cash, representing an approximately 47% premium over the Company’s undisturbed share price on November 10, 2025, the last trading day prior to media reports regarding a potential transaction. The transaction followed a thorough review process overseen by a Special Committee of independent and disinterested members of the Clearw
Visa Redefines Its Role in Travel With the Global Launch of Visa Destinations25.6.2026 16:00:00 CEST | Press release
A new consumer Visa travel platform is now live across 10 locations, including flagship cities such as Paris, London and New York City, with more destinations to be added later this year.This platform connects Visa cardholders with curated experiences and exclusive access aligned to passion-led travel pillars through a consumer mobile-first platform.Global anchor partners include Santander Group, Global Blue, Star Alliance, and Trip.com Group, leaders across the financial and travel ecosystem. Visa (NYSE: V), a global leader in digital payments, today announced the launch of Visa Destinations, a passion-led travel platform live in 10 major locations around the world, as the company redefines its role in the rapidly growing experience-driven travel economy. The move marks a strategic expansion of Visa’s role beyond payments, positioning the company at the center of how travelers discover, plan and experience trips. According to Visa research, travelers are increasingly choosing destinat
Incode Acquires Identiq to Expand Its Privacy-First Architecture for Identity and Fraud Prevention25.6.2026 15:00:00 CEST | Press release
Extends its privacy-by-design architecture with Identiq’s patented cryptographic technology that enables organizations to share fraud signals without sharing sensitive data. Incode Technologies, a global leader in AI-powered identity verification and fraud prevention, today announced that it has completed the acquisition of Identiq, a company specializing in privacy-enhancing cryptographic solutions for peer-to-peer anti-fraud collaboration. Incode announced this acquisition as part of a $100 million commitment to advancing its original privacy-preserving identity infrastructure. The funds will be used to enhance on-device processing capabilities, continue R&D in privacy-enhancing technologies, and expand engineering resources and its global footprint. “We have always believed that privacy and fraud prevention are not a tradeoff, but part of the same problem, solved together or not at all,” said Ricardo Amper, Founder and CEO of Incode. “Identiq is the piece that enhances our Privacy b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom